Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Sight Sciences, Inc. (SGHT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
4Distinct source URLs
12High confidence
0.844Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Sight Sciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DEERFIELD-CAMPBELL-LLC
DEERFIELD-CAMPBELL-LLC
90%
The Second Amendment amends that certain Multi-Tenant Space Lease, dated February 5, 2021, and that certain Commencement Date/Acceptance Agreement, dated August 1, 2021, between the Company and Lesso…
cialize products for eye conditions. Notable competitors with approved MIGS products include Glaukos, Alcon, AbbVie, New World Medical, and Nova Eye Medical Limited. Notable competitors with approved…
Sight Sciences, Inc. Customers
Ticker
Name
Confidence
Evidence
ALCON-INC
ALCON-INC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ALCON-RESEARCH-LLC
ALCON-RESEARCH-LLC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ALCON-VISION-LLC
ALCON-VISION-LLC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
IVANTIS-INC
IVANTIS-INC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ASCS
ASCS
90%
We currently derive the majority of our U.S. revenue from the sale of our OMNI and SION products to ASCs and HOPDs
ECPS
ECPS
90%
We currently derive the majority of our U.S. revenue from the sale of our TearCare products to ECPs
HOPDS
HOPDS
90%
We currently derive the majority of our U.S. revenue from the sale of our OMNI and SION products to ASCs and HOPDs
Reciprocal relationship from HTGC graph: Reciprocal relationship from SGHT graph: in our inventory balance. The non-cash charges primarily consisted of $4.2 million related to stock-based compensatio…
in our inventory balance. The non-cash charges primarily consisted of $4.2 million related to stock-based compensation expense, $0.2 million of accretion of debt discount and debt issuance costs, $0.…
Reciprocal relationship from JNJ graph: Reciprocal relationship from SGHT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SGHT graph: Reciprocal relationship from JNJ grap…
cialize products for eye conditions. Notable competitors with approved MIGS products include Glaukos, Alcon, AbbVie, New World Medical, and Nova Eye Medical Limited. Notable competitors with approved…
Sight Sciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SGHT-DEBT-12502
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-09-30.
SGHT-DEBT
Debt stack $40.8M
90%
Market cache reports total debt of $40.8M.
SGHT-DEBT-12501
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2025-12-31.
Sight Sciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sight Sciences, Inc..
Sight Sciences, Inc. Ownership
Holder
Name
Confidence
Evidence
SGHT-OWNER-LONG-FOCUS-CAPITAL-MANAGEMENT-LL
Long Focus Capital Management, LLC
90%
13F overlay lists Long Focus Capital Management, LLC as top holder; 113 tracked holders.
Sight Sciences, Inc. Extended Supply Chain Network
